Pupillary response

 Inova Health System Expands Adoption of NeurOptics’ Pupillometers in ICUs, Stroke Units and Emergency Departments

Retrieved on: 
Tuesday, July 20, 2021
Medical devices, Health, Hospitals, Practice Management, Other Health, Optical, Branches of biology, Neurological pupil index, Vision, Reflexes, Pupil, Light, Senses, Pupilometer, Pupillometry, Ophthalmology, Pupillary response, Pupillary light reflex, NeurOptics, Inova Health System, NEUROPTICS, INOVA HEALTH SYSTEM

Inova has implemented 135 devices in five hospitals across 20 critical care units and five emergency departments.

Key Points: 
  • Inova has implemented 135 devices in five hospitals across 20 critical care units and five emergency departments.
  • Automated infrared pupillometry using NeurOptics NPi Pupillometer provides nurses and clinicians with an objective assessment of the pupillary light reflex.
  • The NPi Pupillometer measures pupil size and reactivity, which is expressed numerically on the Neurological Pupil index (NPi).
  • Our mission is to provide world-class healthcare every time, every touch to each person in every community we have the privilege to serve.

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

Retrieved on: 
Thursday, May 20, 2021
Mydriasis, Ophthalmology, Pupillary response, Branches of biology, Pupil, Dilation, Academic disciplines, Biology

Karpecki, Pepose, and Kaiser will discuss the large unmet need for a treatment to reverse approximately 100 million pharmacological dilations that occur each year.

Key Points: 
  • Karpecki, Pepose, and Kaiser will discuss the large unmet need for a treatment to reverse approximately 100 million pharmacological dilations that occur each year.
  • An update will be provided on the reversal of mydriasis program, including the remaining steps prior to NDA submission and plans for commercialization.
  • This underscores the potential value of the role of the investigational product candidate Nyxol in improving comfort and daily function after pupil dilation.
  • Ocuphire recently reported positive top-line data for pivotal MIRA-2 Phase 3 trial for treatment of RM in March 2021.

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually

Retrieved on: 
Tuesday, December 29, 2020
Health, FDA, Diabetes, Clinical trials, Pharmaceutical, Optical, Biotechnology, Ophthalmology, Health, Disability, Vision, Medicine, Mydriasis, Near-sightedness, Presbyopia, Pupillary response, Pupil, Eye examination

If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision smart delivery system.

Key Points: 
  • If approved, MydCombi would be the first microdosed ocular therapeutic with a high precision smart delivery system.
  • Pupil dilation is conducted during most of the estimated 80 million office-based comprehensive and diabetic eye exams performed in the U.S. annually.
  • In contrast, MydCombi is delivered by Eyenovias proprietary Optejet dispenser, designed to ensure consistent and easy application of two mydriatic medications in a quick, touchless micro-mist application.
  • Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.